GSA Capital Partners’s Greenwich LifeSciences GLSI Stock Holding History

GSA Capital Partners’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-45,850	Closed	-$405K	–	1658
2023 Q3	$405K	Buy	45,850 +12,441	+37%	+$117K	0.03%	918
2023 Q2	$322K	Buy	33,409 +20,751	+164%	+$232K	0.03%	1008
2023 Q1	$175K	Sell	12,658 -120	-0.9%	-$1.9K	0.02%	1284
2022 Q4	$194K	Buy	+12,778	New	+$146K	0.02%	1195

Other funds holding GLSI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's GLSI Position: Q4 2023 in Review

GSA Capital Partners sold out of Greenwich LifeSciences (GLSI) in Q4 2023, closing a stake of 45,850 shares — an estimated $405K sold.

GSA Capital Partners first reported a position in GLSI in Q4 2022 and held it in 4 quarters. The position peaked at $405K in Q3 2023. 27 funds tracked by Wall St. Rank hold GLSI as of Q4 2023.

GSA Capital Partners reported no remaining Greenwich LifeSciences position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 45,850 Greenwich LifeSciences shares in Q4 2023, an estimated $405K.
GSA Capital Partners first reported a position in Greenwich LifeSciences in Q4 2022 and held it in 4 quarters.
GSA Capital Partners's Greenwich LifeSciences position peaked at $405K in Q3 2023.
27 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.